FortressBiotech優先A FBIOP 深 滬
等待開盤 03-26 09:30:00 美东时间
13.43
+0.170
+1.28%
華盛通- 最 高13.5599
- 今 開13.40
- 成交量 1.16万股
- 最 低 13.00
- 昨 收 13.26
- 總市值 4602.65万
- 52周最高 14.64
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 4.72
- 委 比 96.08%
- 總股本 342.71万
- 歷史最高 20.5506
- 量 比 1.17
- 振 幅 4.22%
- 歷史最低 -1.5766
- 每 手 1
- 風險率 2.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
Journey Medical Corporation (Nasdaq: DERM), a pharmaceutical company focused on dermatological treatments, announced on March 18, 2026, that it will release its year-end 2025 financial results after U.S. markets close on March 25, 2026. A conference call and audio webcast will be held on March 25 at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join by dialing 1-866-777-2509 (U.S.) or 1-412-317-5413 (interna...
03-18 12:30
HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $17 price target.
02-24 00:05
Avenue Therapeutics licenses ATX-04 worldwide for Pompe disease
Avenue Therapeutics licenses ATX-04 worldwide for Pompe disease Avenue Therapeutics, founded by Fortress Biotech Inc., entered into an exclusive worldwide license agreement with Duke University for ATX-04 (clenbuterol) to treat Pompe disease. Avenue said it will advance ATX-04 as an adjunct to enzym
02-23 21:05
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Cyprium Therapeutics已将其罕见儿科疾病优先审评券以2.05亿美元出售，并将部分收益支付给NIH。Sentynl接手ZYCUBO，Cyprium仍享有销售分成和里程碑付款。CEO指出，此交易助力Fortress今年盈利，同时公司在推进基因疗法开发。
02-23 13:30
The top-performing pharma and biotech stocks as group sees resurgence
Pharmaceutical (PJP), (XPH), (PPH) and biotechnology stocks (XBI), (BBH) have officially returned to favor on Wall Street, according to Michael Yee, global head of biotechnology equity research at UBS...
02-14 03:01
Fortress Biotech Announces FDA Approves Its ZYCUBO To Treat Menkes Disease In Pediatric Patients
Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has approved ZYCUBO®
01-13 20:51
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
Fortress Biotech and Cyprium Therapeutics announced the FDA approval of ZYCUBO (copper histidinate) for Menkes disease, the first FDA-approved treatment for this rare pediatric condition. Sentynl Therapeutics assumed responsibility for ZYCUBO’s development and commercialization, transferring a Rare Pediatric Disease Priority Review Voucher (PRV) to Cyprium and offering up to $129 million in milestones. ZYCUBO significantly improves survival in Me...
01-13 12:45
Fortress Biotech Amends Credit Agreement with Oaktree
Fortress Biotech ( ($FBIO) ) has shared an announcement. On December 12, 2025, ...
2025-12-16 06:45
BRIEF-Fortress Biotech, Cyprium Get FDA Acceptance for CUTX-101 NDA Resubmission
Dec 15 (Reuters) - Fortress Biotech Inc FBIO.O: FORTRESS BIOTECH AND CYPRIUM THERAPEUTICS ANNOUNCE FDA ACCEPTANCE OF CUTX-101 NDA RESUBMISSION FORTRESS BIOTECH INC - PDUFA TARGET DATE FOR CUTX-101 SET...
2025-12-15 22:24
Journey Medical Reports Emrosi Shows No Impact on Microbiome in Rosacea Trial
Journey Medical Corporation, a partner of Fortress Biotech Inc., announced the publication of clinical trial results evaluating the impact of Emrosi™ (DFD-29) on the microbial flora of healthy adults ...
2025-12-10 21:32
